Table 1.

Ongoing clinical trials investigating nucleic acid vaccines in cancer.

Clinical Trial Identifier Code	Investigation Plan	Vaccines, Drug/s	Clinical Setting Lines of therapy	Primary Endpoint	Stage of Development	Clinical Trials Status
NCT03970746	64 participants, Non-Randomized, Sequential Assignment, Open label	PDC*lung01, Keytruda Injectable Product, Alimta	Wash out of 4 weeks since last cycle of chemotherapy	DLT	1/2	Recruiting
NCT02439450	121 participants, Non-Randomized, Parallel Assignment, Open label	Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed	Second or later	TEAEs, ORR, PFS	1/2	Active, not recruiting
NCT02960230	49 participants, Non-Randomized, Parallel Assignment, Open label	K27M peptide, Nivolumab	Second line	K27M peptide, Nivolumab	1/2	Recruiting
NCT01773395	123 participants, Randomized, Parallel Assignment, Triple (Participant, Care Provider, Investigator)	GVAX, Busulfan, Fludarabine, Tacrolimus, Methotrexate	First line	18/month PFS	2	Active, not recruiting